Johnson & Johnson Raises Quarterly Dividend 3.1% to $1.34, Marking 64th Consecutive Year of Increases
Johnson & Johnson (NYSE: JNJ), a diversified healthcare company operating in innovative medicine and medical technology, declared a quarterly cash dividend of $1.34 per share, up from the prior $1.30. The increase extends the company's dividend growth streak to 64 consecutive years.
Johnson & Johnson (NYSE: JNJ), a diversified healthcare company operating in innovative medicine and medical technology, announced that its Board of Directors declared a quarterly cash dividend of $1.34 per share, a 3.1% increase from the previous $1.30 per share. The increase marks the company's 64th consecutive year of dividend growth. Read more dividend announcements.
At the new rate, the indicated annual dividend is $5.36 per share, compared to the previous annual rate of $5.20 per share. The dividend is payable to shareholders of record at the close of business on May 26, 2026.
| Dividend Detail | Date/Amount |
|---|---|
| Dividend Amount | $1.34 per share |
| Previous Amount | $1.30 per share |
| Percentage Increase | 3.1% |
| Record Date | May 26, 2026 |
| Ex-Dividend Date | May 26, 2026 |
| Payment Date | June 9, 2026 |
| New Annual Indicated Dividend | $5.36 per share |
First Quarter Performance
The dividend announcement accompanied the company's first quarter 2026 earnings report. Johnson & Johnson reported sales of $24.1 billion for the quarter ended March 29, 2026, representing reported growth of 9.9%. Operational growth, which excludes currency translation effects, was 6.4% for the period.
The company reported earnings per share of $2.14 for the first quarter, with adjusted earnings per share of $2.70. Johnson & Johnson raised its full-year 2026 guidance, estimating reported sales of $100.8 billion, representing 7.0% growth at the midpoint, and adjusted earnings per share of $11.55, or 7.1% growth at the midpoint.
MedTech Division Results
The company's MedTech division reported worldwide sales of $8.6 billion for the first quarter, up 7.7% on a reported basis and 4.6% operationally. U.S. sales in the division totaled $4.5 billion, up 5.9%, while international sales reached $4.2 billion, up 9.7% reported and 3.2% operationally.
Within the Orthopaedics segment, worldwide sales reached $2.4 billion, up 6.3% reported and 3.2% operationally. The Cardiovascular division posted worldwide sales of $1.4 billion, representing 6.7% reported growth and 3.6% operational growth. The Contact Lenses and Other category generated $969 million in worldwide sales, up 5.5% reported and 2.7% operationally.